Heuser Health settles skin-substitute overbilling allegations
Oct 4, 2026 edition · GC-2026-0041 · Published 2026-10-04 · Version 2 · Settled
Heuser Health agreed to pay $2,646,186.72 over allegations that skin-substitute claims overstated actual invoice costs.
What happened
DOJ's September 2, 2026 release announced that Heuser Health, a Louisville provider of at-home wound care, agreed to pay $2,646,186.72 to resolve False Claims Act allegations involving Medicare and TRICARE skin-substitute claims. The settlement forms part of the department's broader Operation Skin Scam initiative. DOJ expressly states that the claims are allegations only and there was no determination of liability. The release establishes an agreement to pay, rather than independent proof of completed payment.
Heuser used advanced bioengineered or tissue-derived skin substitutes to treat chronic and acute wounds. According to DOJ, the federal rules applicable to these claims required billing based on actual invoice price, but the company allegedly submitted or caused claims using invoice amounts higher than its true purchase prices. The alleged mismatch concerned acquisition cost and reimbursement, rather than a finding that every wound-care service was unnecessary. Its operational relevance is to claims that actually use invoice-based reimbursement; the case does not establish one payment methodology for all products, payers or care settings.
Scope and timing
- Authority status
- Settled
- Applicability
- Operationally relevant
- Audience
- Health systems, Provider networks
- Jurisdiction
- Federal
Why it matters
Invoice-supported claims must reconcile to actual acquisition costs under the applicable payment rule, including relevant credits and discounts.
Recommended action
Reconcile applicable skin-substitute claims to purchase records and actual costs, review credits or discounts, and document the payer rule used for the claim.
Case details
- agencies
- DOJ
- entities
- Heuser Health
- action Type
- Settlement
- event Date
- 2026-09-02
- alleged Conduct
- Claims allegedly used invoice amounts above the true purchase price.
- resolution
- Agreement to pay $2,646,186.72 to resolve civil False Claims Act allegations; no determination of liability or proof of completed payment in the release.
Operational lessons
- Reconcile invoice-supported claims to actual acquisition costs.
- Review credits and discounts before finalizing claims.
Sources
- Heuser Health settles skin-substitute overbilling allegationsOfficial · DOJ, Western District of Kentucky · 2026-09-02 · Source review 2026-09-06
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Enforcement Briefing report →